ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,294 | $1,313 | $1,075 |
| - Cash | $263 | $218 | $150 | $145 |
| + Debt | $307 | $320 | $623 | $624 |
| Enterprise Value | – | $1,396 | $1,786 | $1,554 |
| Revenue | $228 | $211 | $197 | $191 |
| % Growth | 7.8% | 7.2% | 3.4% | – |
| Gross Profit | $112 | $137 | $124 | $110 |
| % Margin | 49.1% | 64.7% | 62.9% | 57.9% |
| EBITDA | $61 | $39 | $48 | $15 |
| % Margin | 26.8% | 18.6% | 24.5% | 7.8% |
| Net Income | $24 | $9 | $16 | -$10 |
| % Margin | 10.6% | 4% | 8% | -5.4% |
| EPS Diluted | 1.13 | 0.36 | 0.69 | -0.55 |
| % Growth | 213.9% | -47.8% | 225.5% | – |
| Operating Cash Flow | $44 | $76 | $35 | $16 |
| Capital Expenditures | -$6 | -$7 | -$20 | -$2 |
| Free Cash Flow | $38 | $69 | $15 | $13 |